Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2008

Jiang Xiaofeng, Zhou Jun, Yuen Noah K, Corless Christopher L, Heinrich Michael C, Fletcher Jonathan A, Demetri George D, Widlund Hans R, Fisher David E, Hodi F Stephen

Abstract excerpt

PURPOSE: Melanoma subtypes based on anatomic location and UV light exposure can be further classified based on genetic alterations recently identified. Mutations and gene amplification in KIT have been described in a significant percentage of mucosal and acral melanomas. We recently reported a patient with metastatic mucosal melanoma harboring a known KIT mutation treated with imatinib mesylate who experienced a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Melanoma

Share to Mucous Membrane

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 19047099
DOI: 10.1158/1078-0432.CCR-08-1144

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib targeting of KIT-mutant oncoprotein in melanoma.PMID 19047099Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.Semantic proximity Read ↗

Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations.Semantic proximity Read ↗

KIT gene mutations and copy number in melanoma subtypes.Semantic proximity Read ↗

KIT mutations in a series of melanomas and their impact on treatment with imatinib.Semantic proximity Read ↗

Somatic Activation of KIT in Distinct Subtypes of MelanomaSemantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.